Ticker Details
Axsome Therapeutics, Inc. Axsome Therapeutics Inc is a pharmaceutical company in the United States. It focuses on developing novel therapeutics for the redressal of diseases related to the central nervous system.
IPO Date:	November 19, 2015
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$10.88B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$1.52 | 3.27%
Avg Daily Range (30 D):	$4.82 | 2.13%
Avg Daily Range (90 D):	$4.39 | 1.97%

Institutional Daily Volume
Avg Daily Volume:	.61M
Avg Daily Volume (30 D):	.54M
Avg Daily Volume (90 D):	.63M

Trade Size
Avg Trade Size (Sh.):	72
Avg Trade Size (Sh.) (30 D):	36
Avg Trade Size (Sh.) (90 D):	41

Institutional Trades
Total Institutional Trades:	3,887
Avg Institutional Trade:	$4.48M
Avg Institutional Trade (30 D):	$15.96M
Avg Institutional Trade (90 D):	$19.07M
Avg Institutional Trade Volume:	.05M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$5.88M
Avg Closing Trade (30 D):	$26.28M
Avg Closing Trade (90 D):	$33.61M
Avg Closing Volume:	59.8K

News

Jul 14, 2026 @ 11:00 AM Axsome Therapeutics to Report Second Quarter 2026 ... Source: Na

Jul 6, 2026 @ 10:10 PM These 3 Stocks Trounced the S&P 500 in the First H... Source: Adria Cimino

Jul 2, 2026 @ 12:05 PM Is Axsome Therapeutics Stock a Millionaire Maker? ... Source: Adria Cimino

Jun 26, 2026 @ 11:00 AM Axsome Therapeutics Initiates FOCUS-3 Phase 3 Tria... Source: Axsome Therapeutics

Jun 17, 2026 @ 1:18 AM Hypercharge Announces Issuance of Equity Grants Source: Hypercharge Networks Corp.

Financials
	TTM	Q2 2026	Q1 2026
Basic EPS	$-3.74	$-.99	$-1.26
Diluted EPS	$-3.74	$-.99	$-1.26
Revenue	$776.57M	$218.38M	$191.2M
Gross Profit
Net Income / Loss	$-191.64M	$-51.31M	$-64.54M
Operating Income / Loss	$-186.07M	$-49.65M	$-63.36M
Cost of Revenue
Net Cash Flow	$16.83M	$14.74M	$-17.83M
PE Ratio